These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11784135)

  • 1. Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates.
    Mandagere AK; Thompson TN; Hwang KK
    J Med Chem; 2002 Jan; 45(2):304-11. PubMed ID: 11784135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery.
    Stoner CL; Cleton A; Johnson K; Oh DM; Hallak H; Brodfuehrer J; Surendran N; Han HK
    Int J Pharm; 2004 Jan; 269(1):241-9. PubMed ID: 14698595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
    Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
    Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties.
    Yang Z; Zadjura LM; Marino AM; D'Arienzo CJ; Malinowski J; Gesenberg C; Lin PF; Colonno RJ; Wang T; Kadow JF; Meanwell NA; Hansel SB
    J Pharm Sci; 2010 Apr; 99(4):2135-52. PubMed ID: 19780144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.
    Gertz M; Harrison A; Houston JB; Galetin A
    Drug Metab Dispos; 2010 Jul; 38(7):1147-58. PubMed ID: 20368326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
    Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
    Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog.
    Kamath AV; Chang M; Lee FY; Zhang Y; Marathe PH
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):145-53. PubMed ID: 15830240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction.
    Liu F; Zhuang X; Yang C; Li Z; Xiong S; Zhang Z; Li J; Lu C; Zhang Z
    Biopharm Drug Dispos; 2014 Jul; 35(5):296-307. PubMed ID: 24647883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
    Marathe P; Tang Y; Sleczka B; Rodrigues D; Gavai A; Wong T; Christopher L; Zhang H
    J Pharm Sci; 2010 Aug; 99(8):3579-93. PubMed ID: 20166197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
    Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K
    Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Metabolic Stability and Permeability of Gymnemagenin and Its In Vivo Pharmacokinetic Correlation in Rats - A Pilot Study.
    Bera R; Kundu A; Sen T; Adhikari D; Karmakar S
    Planta Med; 2016 Apr; 82(6):544-50. PubMed ID: 26916641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
    Williams J; Siramshetty V; Nguyễn ÐT; Padilha EC; Kabir M; Yu KR; Wang AQ; Zhao T; Itkin M; Shinn P; Mathé EA; Xu X; Shah P
    Bioorg Med Chem; 2022 Feb; 56():116588. PubMed ID: 35030421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
    Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
    Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics.
    Gu Y; Wang J; Li K; Zhang L; Ren H; Guo L; Sai Y; Zhang W; Su W
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):95-115. PubMed ID: 24817647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.
    Pasha MK; Jayaraman R; Reddy VP; Yeo P; Goh E; Williams A; Goh KC; Kantharaj E
    Drug Metab Lett; 2012 Mar; 6(1):33-42. PubMed ID: 22372550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
    Zhou L; Dockens RC; Liu-Kreyche P; Grossman SJ; Iyer RA
    Drug Metab Dispos; 2012 Jun; 40(6):1093-103. PubMed ID: 22381334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of
    K Pinjari MJS; Somani R; Gilhotra RM
    Indian J Pharmacol; 2017; 49(4):297-303. PubMed ID: 29326490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability.
    Lau YY; Chen YH; Liu TT; Li C; Cui X; White RE; Cheng KC
    Drug Metab Dispos; 2004 Sep; 32(9):937-42. PubMed ID: 15319334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.